<DOC>
	<DOCNO>NCT02269904</DOCNO>
	<brief_summary>SinoFuan kind Fluorouracil Implants intraperitoneal chemotherapy operation treatment gastric cancer . The indication bee approve Chinese FDA . The study post-marketing study . The subject divide two group ( Group A Group B ) . The subject Group A receive D2 radical gastrectomy ( R0 ) , Sinofuan operation 6 cycle Xelox adjuvant chemotherapy.The subject Group B receive D2 radical gastrectomy ( R0 ) , 6 cycle Xelox adjuvant chemotherapy . The subject 's benefit SinoFuan analyze compare 3 year DFS two group .</brief_summary>
	<brief_title>Fluorouracil Implants Used Intraperitoneal Chemotherapy During Operation Treatment Phase III Gastric Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. primary gastric cancer , Phase III 2 . D2 radical gastrectomy ( R0 ) 3 . 18 year old 4 . KPS≥70 % ； 5. suitable hematologic function : ANC≥1.5×109/L , PLC≥80×109/L 6. suitable liver function : Total bilirubin≤1.5×normal ULN , AST ALT≤2.5×normal ULN . 7. suitable renal function : Cr≤1.5×normal ULN , Ccr≥50 ml/min 8 .for female subject , pregnancy test must negative 27 hour enrollment . 9. authorized ICF must sign 1. noninitial gastric cancer； 2. uncontrolled disease . 3. obvious loss weight ( 10 % within 6 week ) 4. female pregnancy feed . 5. contraindication study drug 6. participate clinical trial time treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>